The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | Belantamab mafodotin for myeloma: Phase 1 data & patient-reported outcomes
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the data on the BCMA-directed antibody-drug conjugate belantamab mafodotin (GSK2857916) from the first-in-human Phase I trial (DREAMM-1; NCT02064387) and patient-reported outcomes. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
